Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

Concepts (128)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
167
0.900
Why?
Anus Neoplasms
1
2018
31
0.710
Why?
Bone Marrow Neoplasms
1
2015
15
0.600
Why?
Embolism
1
2015
26
0.590
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1027
0.590
Why?
African Americans
2
2016
717
0.580
Why?
Gene Regulatory Networks
1
2016
124
0.570
Why?
Tumor Lysis Syndrome
1
2014
7
0.560
Why?
Carcinoma, Squamous Cell
1
2018
400
0.530
Why?
Neoplasm Recurrence, Local
1
2018
597
0.530
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
75
0.530
Why?
Pyrazoles
1
2014
119
0.520
Why?
Pyrimidines
1
2014
199
0.490
Why?
Biliary Tract Diseases
1
2012
12
0.480
Why?
Actinomycosis
1
2012
10
0.480
Why?
Salvage Therapy
1
2013
146
0.480
Why?
Angiogenesis Inhibitors
2
2006
217
0.480
Why?
Stomach Neoplasms
1
2015
168
0.470
Why?
Bile Duct Neoplasms
1
2012
30
0.470
Why?
Clinical Trials as Topic
5
2019
502
0.470
Why?
Benzenesulfonates
2
2011
13
0.430
Why?
Prognosis
6
2019
2105
0.420
Why?
Carcinoma, Hepatocellular
1
2013
194
0.420
Why?
Gene Expression Profiling
1
2016
1119
0.410
Why?
Middle Aged
12
2020
13662
0.390
Why?
Stroke
1
2015
531
0.390
Why?
Pyridines
2
2011
144
0.390
Why?
Colorectal Neoplasms
2
2003
235
0.380
Why?
Liver Neoplasms
1
2013
336
0.380
Why?
Drug Industry
1
2007
40
0.320
Why?
Hypertensive Encephalopathy
1
2006
4
0.320
Why?
raf Kinases
1
2006
5
0.320
Why?
Heparin
1
2007
102
0.320
Why?
Communication Barriers
1
2007
41
0.320
Why?
Aged, 80 and over
6
2018
3636
0.320
Why?
Thrombocytopenia
1
2007
95
0.320
Why?
Thiazolidinediones
1
2007
105
0.310
Why?
Aged
9
2020
10457
0.280
Why?
Anticoagulants
1
2007
273
0.270
Why?
Thrombosis
1
2007
266
0.270
Why?
Skin
1
2007
443
0.270
Why?
Adult
9
2020
14371
0.260
Why?
Enzyme Inhibitors
1
2006
471
0.250
Why?
Female
11
2020
28954
0.250
Why?
Prostatic Neoplasms
1
2007
412
0.250
Why?
Survival Rate
2
2018
1016
0.240
Why?
Humans
16
2020
52992
0.230
Why?
Camptothecin
1
2002
18
0.230
Why?
Follow-Up Studies
3
2019
2451
0.230
Why?
Diabetes Mellitus, Type 2
1
2007
457
0.220
Why?
Lung Neoplasms
1
2007
599
0.220
Why?
Antineoplastic Agents, Phytogenic
1
2002
90
0.220
Why?
Male
10
2020
28328
0.210
Why?
Oximes
1
2020
11
0.210
Why?
Pyrimidinones
1
2020
17
0.210
Why?
Pyridones
1
2020
43
0.200
Why?
Thalidomide
1
2002
405
0.190
Why?
Imidazoles
1
2020
153
0.190
Why?
Cholangiocarcinoma
2
2011
28
0.190
Why?
Protein Kinase Inhibitors
1
2020
217
0.180
Why?
Survival Analysis
3
2020
799
0.160
Why?
Melanoma
1
2020
319
0.160
Why?
Antineoplastic Agents
2
2019
1290
0.160
Why?
Neoplasm Staging
2
2013
810
0.150
Why?
Combined Modality Therapy
1
2018
713
0.150
Why?
Severity of Illness Index
1
2019
1117
0.140
Why?
Gene Amplification
1
2015
59
0.140
Why?
Polycomb Repressive Complex 2
1
2015
50
0.140
Why?
Adenine
1
2014
46
0.140
Why?
Genes, myc
1
2015
48
0.140
Why?
Retrospective Studies
3
2018
6077
0.140
Why?
Antibodies, Monoclonal
1
2019
565
0.130
Why?
Skin Neoplasms
1
2020
548
0.130
Why?
Piperidines
1
2014
103
0.130
Why?
United States
3
2019
5092
0.130
Why?
Registries
3
2007
553
0.130
Why?
Gene Deletion
1
2015
292
0.130
Why?
Quinazolines
1
2013
38
0.120
Why?
Leukemia, Myeloid, Acute
1
2015
178
0.120
Why?
Actinomyces
1
2012
9
0.120
Why?
Treatment Outcome
4
2020
5644
0.120
Why?
Endoscopy, Gastrointestinal
1
2012
77
0.110
Why?
Gallbladder Neoplasms
1
2011
8
0.110
Why?
Comorbidity
2
2019
698
0.110
Why?
Gene Expression Regulation, Neoplastic
1
2016
895
0.110
Why?
Antibodies, Monoclonal, Humanized
1
2013
232
0.110
Why?
Phenylurea Compounds
2
2011
15
0.110
Why?
Niacinamide
2
2011
25
0.110
Why?
Incidence
2
2019
1095
0.100
Why?
Neoplasms
1
2019
1260
0.090
Why?
Causality
1
2007
50
0.080
Why?
Necrosis
1
2007
199
0.080
Why?
Drugs, Investigational
1
2007
20
0.080
Why?
Hospitals, University
1
2007
96
0.080
Why?
Confidence Intervals
1
2007
178
0.080
Why?
Probability
1
2007
187
0.080
Why?
United States Food and Drug Administration
1
2007
98
0.080
Why?
Neoplasm Metastasis
2
2011
265
0.080
Why?
Age Distribution
1
2007
210
0.080
Why?
Tomography, X-Ray Computed
1
2012
1295
0.080
Why?
Anti-Bacterial Agents
1
2012
794
0.080
Why?
Medical Oncology
1
2007
109
0.070
Why?
Syndrome
1
2006
260
0.070
Why?
Patient Selection
1
2007
299
0.070
Why?
Publication Bias
1
2005
15
0.070
Why?
Editorial Policies
1
2005
13
0.070
Why?
Periodicals as Topic
1
2005
70
0.060
Why?
Dose-Response Relationship, Drug
1
2007
1572
0.060
Why?
Risk Assessment
1
2007
1417
0.060
Why?
MAP Kinase Kinase Kinases
1
2020
19
0.050
Why?
Socioeconomic Factors
1
2003
637
0.050
Why?
Proto-Oncogene Proteins B-raf
1
2020
89
0.050
Why?
Mutation, Missense
1
2020
117
0.050
Why?
Trisaccharides
1
2019
1
0.050
Why?
Premedication
1
2019
19
0.050
Why?
Drug Administration Schedule
1
2020
428
0.050
Why?
Administration, Oral
1
2020
481
0.050
Why?
Infusions, Intravenous
1
2019
245
0.050
Why?
Antibodies
1
2019
175
0.040
Why?
Health Services Accessibility
1
2003
435
0.040
Why?
Magnetic Resonance Imaging
1
2006
1724
0.040
Why?
Disease Management
1
2019
200
0.040
Why?
Arkansas
1
2003
2193
0.040
Why?
Adolescent
1
2007
6887
0.030
Why?
In Situ Hybridization, Fluorescence
1
2015
274
0.030
Why?
Polymorphism, Single Nucleotide
1
2015
570
0.030
Why?
Young Adult
1
2020
4310
0.030
Why?
Disease-Free Survival
1
2011
522
0.020
Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description